LigaChem Biosciences (141080) stock
KOSDAQ · Pharmaceuticals
As of the Nov 16 regular-session close (Korea)
- Market cap
- KRW 2.1 trillion
- As of Nov 16, 2026
- P/E
- -9.08x
- Trailing twelve months
- P/B
- 4.43x
- Latest reported equity
- P/S
- 28.54x
- Trailing twelve months
- ROE
- -48.8%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 2.1 trillion
- As of Nov 16, 2026
- P/E
- -9.08x
- Trailing twelve months
- P/B
- 4.43x
- Latest reported equity
- P/S
- 28.54x
- Trailing twelve months
- ROE
- -48.8%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-9.08x
Net loss — not comparable
P/B
4.43x
P/S
28.54x
Earnings and dividend metrics▾
Earnings
EPS
-KRW 6,104
Earnings per share
BPS
KRW 12,502
Book value per share
ROE
-48.8%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at KRW 6,104 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 12,502 of net assets.
- ROE — shareholder equity shrank by 48.8% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 14, 2026 | KRW 5.5 billion | -KRW 72 billion | -KRW 68.1 billion | -83.0% |
| Q1 2026Consolidated · Filed May 15, 2026 | KRW 35.9 billion | -KRW 37.4 billion | -KRW 33.3 billion | -30.4% |
| Q4 2025Consolidated · Filed Mar 23, 2026 | KRW 16 billion | -KRW 73.1 billion | -KRW 64.6 billion | — |
| Q3 2025Consolidated · Filed Nov 14, 2025 | KRW 41.4 billion | -KRW 23.2 billion | -KRW 15.3 billion | — |
| Q2 2025Consolidated · Filed Aug 14, 2025 | KRW 32.6 billion | -KRW 21.5 billion | -KRW 38.1 billion | — |
| Q1 2025Consolidated · Filed May 15, 2025 | KRW 51.6 billion | KRW 11.4 billion | KRW 26.5 billion | — |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 23, 2026 | KRW 141.6 billion | -KRW 106.5 billion | -KRW 91.6 billion | — |
| FY2024Consolidated · Filed Mar 21, 2025 | KRW 125.9 billion | -KRW 20.9 billion | KRW 7.8 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 10.01%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 1.97 billion
- Previous 20-day average 13.28%
- Net short position
- 64,630 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 2,814,988 shares
- As of Nov 13, 2026 · 7.60% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 10.01% | KRW 1.97 billion |
| Nov 12, 2026 | 11.38% | KRW 2.32 billion |
| Nov 11, 2026 | 9.72% | KRW 3.4 billion |
| Nov 10, 2026 | 16.69% | KRW 2.61 billion |
| Nov 9, 2026 | 30.39% | KRW 7.56 billion |
| Nov 6, 2026 | 2.07% | KRW 450 million |
| Nov 5, 2026 | 7.86% | KRW 2.81 billion |
| Nov 4, 2026 | 13.72% | KRW 3.56 billion |
| Nov 3, 2026 | 14.82% | KRW 1.7 billion |
| Nov 2, 2026 | 9.18% | KRW 900 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Report on Major Holdings of Shares (Short Form)Oct 2, 2026 · Major Holding ReportEnglish
- Material Management InformationSep 30, 2026English
- Technology or Regulatory Approval(Korean)Aug 7, 2026
- Report on Major Holdings of Shares (General Form)(Korean)Aug 4, 2026 · Major Holding Report
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Aug 4, 2026 · Insider Ownership Report
- Report on Major Holdings of Shares (General Form)(Korean)Aug 4, 2026 · Major Holding Report
- Report on Major Holdings of Shares (Short Form)(Korean)Jul 31, 2026 · Major Holding Report
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Jul 24, 2026 · Insider Ownership Report
Filings with a published English version open in English; the rest link to the Korean original.
LigaChem Biosciences (141080) stock information
KOSDAQ
LigaChem Biosciences (141080) is listed on KOSDAQ. Its market capitalization is about KRW 2.1 trillion. On trailing-twelve-month earnings the P/E ratio is -9.08, and the P/B ratio is 4.43. Return on equity is -48.8%. These figures are computed in-house from official filings and are reference information only.
LigaChem Biosciences — frequently asked questions
- What is the P/E ratio of LigaChem Biosciences (141080)?
- On a trailing-twelve-month basis, 141080 trades at a P/E ratio of -9.08. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of LigaChem Biosciences?
- 141080 has a market capitalization of about KRW 2.1 trillion. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.